DSM-Firmenich AG
DSFIR: XAMS (NLD)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|$! | LOCK|lw^ | LOCK|#$bhj^ |
DSM-Firmenich Earnings: Good Start to 2025 Amid Reshaping Portfolio
DSM-Firmenich reported first-quarter 2025 organic sales growth of 8% and EBITDA of EUR 650 million, 40% higher than the prior year. The results include a one-off positive price impact from the vitamin supply disruption. The full-year guidance was confirmed.
